Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions

Introduction and objectives: Transcatheter implantation of balloon-expandable valves in non-aortic positions represents a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients. We assessed 4-year clinical outcomes and echocardiographic performance of the transcatheter heart valve Myval THV implanted in the mitral, tricuspid, and pulmonary positions. Methods: This retrospective multicenter study included a total of 50 patients (mitral n = 33; tricuspid n = 13; pulmonary n = 4) treated across 11 centers, with clinical follow-up extending to 4 years and echocardiographic assessment of surviving patients. Results: Technical successs was achieved in 96.9% of mitral cases (1 procedural death) and in 100% of tricuspid and pulmonary cases. At 1 year, death had occurred in 2/33 (6.1%) mitral patients and in none of the tricuspid or pulmonary patients. At 4 years, death had occurred in 4/33 (12.1%) mitral, 2/13 (15.3%) tricuspid, and 0/4 pulmonary patients; stroke occurred in 0/33, 1/13 (7.6%), and 0/4 patients, respectively. Mean transvalvular gradients at 4 years were 8.5 ± 3.3 mmHg (mitral), 3.8 ± 1.6 mmHg (tricuspid), and 12.7 ± 9.9 mmHg (pulmonary). No moderate or greater bioprosthetic regurgitation was observed at 4-year echocardiographic assessment, and no valve reinterventions were recorded during follow-up. Conclusions: In this multicenter cohort, off-label use of the Myval THV in non-aortic positions demonstrated adequate midterm clinical outcomes and sustained echocardiographic performance up to 4 years. These preliminary findings support the feasibility of this transcatheter approach in selected patients but require further prospective validation.

Authors

Institutions

Publication Details

Journal
REC interventional cardiology (English Edition)
Published
2026-11-16
DOI
https://doi.org/10.24875/recice.m26000632
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions

Filippo Pensotti, Krešimir Štambuk, Henrik Nissen, Manuel Carrasco‐Moraleja et al.
2 links
REC interventional cardiology (English Edition)
Cardiac Valve Diseases and Treatments
article

Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions

Filippo Pensotti, Krešimir Štambuk, Henrik Nissen, Manuel Carrasco‐Moraleja, Sengottuvelu Gunasekaran, Marcelo Rodríguez Murillo, Ashok Seth, Mauricio Zúñiga, Carlos Cortés, Mathias Dyreborg Jørgensen, A. Jurado Román, Silvia Vallinas‐Hernández, Akash Jain, Pedro Martin, JOHN JOSE, Matteo Montorfano, Marcio Montenegro da Costa, Phillip Freeman, Mussayev Abdurashid, Ignacio J. Amat-Santos, Mario García-Gómez, Cristhian Aristizabal
article en

Abstract

Introduction and objectives: Transcatheter implantation of balloon-expandable valves in non-aortic positions represents a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients. We assessed 4-year clinical outcomes and echocardiographic performance of the transcatheter heart valve Myval THV implanted in the mitral, tricuspid, and pulmonary positions. Methods: This retrospective multicenter study included a total of 50 patients (mitral n = 33; tricuspid n = 13; pulmonary n = 4) treated across 11 centers, with clinical follow-up extending to 4 years and echocardiographic assessment of surviving patients. Results: Technical successs was achieved in 96.9% of mitral cases (1 procedural death) and in 100% of tricuspid and pulmonary cases. At 1 year, death had occurred in 2/33 (6.1%) mitral patients and in none of the tricuspid or pulmonary patients. At 4 years, death had occurred in 4/33 (12.1%) mitral, 2/13 (15.3%) tricuspid, and 0/4 pulmonary patients; stroke occurred in 0/33, 1/13 (7.6%), and 0/4 patients, respectively. Mean transvalvular gradients at 4 years were 8.5 ± 3.3 mmHg (mitral), 3.8 ± 1.6 mmHg (tricuspid), and 12.7 ± 9.9 mmHg (pulmonary). No moderate or greater bioprosthetic regurgitation was observed at 4-year echocardiographic assessment, and no valve reinterventions were recorded during follow-up. Conclusions: In this multicenter cohort, off-label use of the Myval THV in non-aortic positions demonstrated adequate midterm clinical outcomes and sustained echocardiographic performance up to 4 years. These preliminary findings support the feasibility of this transcatheter approach in selected patients but require further prospective validation.

REC interventional cardiology (English Edition)
Apollo Hospitals (IN), Vita-Salute San Raffaele University (IT), Christian Medical College, Vellore (IN), Aalborg University Hospital (DK), Odense University Hospital (DK), San Raffaele University of Rome (IT), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Fortis Escorts Heart Institute (IN), Christian Medical College (IN), Apollo Hospitals (IN), Astana Medical University (KZ), Hospital Clínico Universitario de Valladolid (ES)
Good health and well-being
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon